All News
GCs on MACE in RA in VA
A#2430 #ACR23 @RheumNow
Not just ongoing steroid usage, also prior usage 1 year ago
5 mg use for 30 days one year ago - increases MACE events by 3%
5 mg use for 90 days one year ago - increases MACE events by 9%
Eric Dein ( View Tweet)
Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest @RheumNow https://t.co/50B5nGqxu9 https://t.co/lNrUbZOm0o
Richard Conway ( View Tweet)
Even low doses of steroids associated with major adverse cardiovascular events!
Large VA database - >18k RA pts
Dose as low as 5mg/day prednisone for 30 days, 1 year prior to event, associated with increased MACE
@RheumNow #ACR23 Abs#2430 https://t.co/JjeoBi7YTD
Robert B Chao, MD ( View Tweet)
Mok et al. Romosozumab superior to denosumab in high risk GIO. Superior in improving spine BMD. Not fracture. Fracture is what matters. Abstr#2429 #ACR23 @RheumNow https://t.co/5ModHOGsED
Richard Conway ( View Tweet)
A#2429 #ACR23 @RheumNow
ROMO v DEN - 12 mo RCT 70 GIOP pts at high-risk
Mean prednisolone dose 6.6 mg
H/o fragility fx in 1/2 pts
12 mo: Increase in spine BMD- ROMO (+7) and DEN (+2)
Hip and Femoral neck improved both (1.6% both), not signif diff bw grps
AEs: incr injxn site rxn https://t.co/VueuZIjFfM
Eric Dein ( View Tweet)
Physical therapy and lifestyle counseling the main pillars of #OA management are underutilized!
Mainstay remains weight loss and exercise! @RheumNow #ACR23
Rrf memorial lecture @Tuhina_Neogi https://t.co/yXqWIEccq4
Bella Mehta bella_mehta ( View Tweet)
McCormick et al. No improvement in premature mortality gap in gout over time. 19% increased mortality in gout. Independent of serum urate and CV risk factors. Abstr#2428 #ACR23 @RheumNow https://t.co/lSoEvajN3O https://t.co/uWNokm7LCT
Richard Conway ( View Tweet)
Gout mortality
A#2428 #ACR23 @RheumNow
1988-1994 (early) v 2007-2016 (late): Has not improved over time
Independent of serum uric acid
Female gout: increased mortality
Black gout pts also increased
Conclusion: the inflammation, not the uric acid is the risk https://t.co/LTFoSFzaBu
Eric Dein ( View Tweet)
The DICKENS study showed no significant improvement in knee pain(p=0.77), WOMAC pain(p=0.64) or function(p=0.68) & stiffness(p=0.34) between diacerin and pbo over 24wks.
⬆️AEs in diacerin grp-diarrhea, colored urine
#ACR23 ABSTL05 @RheumNow https://t.co/ht0pGN38il
sheila ( View Tweet)
Super interesting SpA phenotypical type world map. #ACR23 Abs #2195 continues to prove how heterogenous this disease is and the need for additional therapeutic agents for improved patient outcomes. https://t.co/hpKY7usUUb @rheumnow https://t.co/xJ1bx6wOC0
Dr. Rachel Tate ( View Tweet)
A#2427 #ACR23 @RheumNow
PR3+ cell abundance higher in prolif LN, more than membranous. Mostly in tuberulointerstitium
Density of PR3+ higher in glomueruli of prolif LN
Correlates with activity, not chronicity
Urinary PR3 predict renal fxn loss at 3y
@jhrheumatology @andreafava https://t.co/vvC8lgZgWO
Eric Dein ( View Tweet)
APTURA 1 study of tocilizumab biosimilar. Not surprisingly no difference. I'm excited about this product. Hopefully be the end to our tocilizumab supply issues and significant societal savings Abstr#0445 #ACR23 @RheumNow https://t.co/qvP7LCeAkm https://t.co/Zb1FUAlXlz
Richard Conway ( View Tweet)
What drives fate of synovial fibroblast into being a lining fibroblast?
Presti et al., organoid culture approach:
-Beta catenin seems instrumental
-Cadherin 23 is specific & drives compaction
Big implications for elective FLS targeted ttmt!
@RheumNow #ACR23 ABST2426 https://t.co/9R5AhwE9rQ
Aurelie Najm ( View Tweet)
Lung cancer in RA. @NamrataRheum et al. 26,625 RA HR for lung cancer for b/tsDMARDs vs csDMARDS 1.07 (0.91-1.26) Abstr#0453 #ACR23 @RheumNow https://t.co/NLNtyYoaoH https://t.co/tRpt62n62X
Richard Conway ( View Tweet)
Comorbidities, including heightened CV risk, are linked to severe psoriasis. However, understanding subclinical CV disease timing in psoriasis patients remains limited. Dr. Jack Cush at .@RheumNow explains why more research is needed in this area: https://t.co/3KqQavVEbP https://t.co/Xo8SH0RTh9
RWCS RWCSmtg ( View Tweet)
@rheumnow and Dr Kevin Winthrop #ACR23 - watch what they to say about #COVID #vaccines on https://t.co/2zKD625Yn9 https://t.co/9tCOgNLyO7
TheDaoIndex KDAO2011 ( View Tweet)
MANDARA -52wk,ph3 non-inferiority study comparing efficacy & safety of benralizumab & mepolizumab in EGPA receiving SOC
👉Benralizumab was non-inferior to mepolizumab in achieving remission at wks 36 & 48 (2.71%; 95% CI –12.54, 17.96; p=0.7278)
#ACR ABSTL14 @RheumNow #ACRbest https://t.co/S3aa3g5mnN
sheila ( View Tweet)
K-drama!
Korean database noted smokers and ex-smokers had less OA fewer TKR! These were age, comorbidities matched. Unclear what the data is for sex difference or occupation. Other pubs in the past noted similar observations. Abst#1808 @rheumnow #ACR23 @UnaMakris https://t.co/ZkjWoxD8wD
TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 Abstr#2270 What are the causes of discordance btw #SLE patients and physicians pertaining to disease activity? Survey data from Global COVAD: 45% rate of discordance! Could be related to fatigue levels, pain, poor mental being & impaired physical function @RheumNow https://t.co/kVzGRJm2R8
Md Yuzaiful Md Yusof ( View Tweet)
Great research by @andreafava on urinary biomarkers for lupus nephritis A#0850 #ACR23
IL-17 and other biomarkers can predict renal fxn loss - better than proteinuria!
Article on @RheumNow https://t.co/DeiWFKzNxC
Eric Dein ( View Tweet)